Medytox announced on October 6th that it has hired Mr. Choi Sung-Cheol (pictured) as general manager of its Osong Plant 2, which is pursuing cGMP certification to enter the global advanced market.
Mr. Choi is a GMP expert who graduated from Korea University with an undergraduate degree in biology and completed his master's and doctoral degrees in microbiology and bioindustry laws, respectively, at the graduate school of the same university.
Mr. Choi said, "I am honored to join Medytox, a company with world-class R&D capabilities in the field of botulinum toxin. I will do my best to contribute to its global expansion with my long-standing experience in various fields such as bioprocess development and production, and plant construction management.“
Medytox Osong Plant 2 is a production facility dedicated to MT10109L, a liquid botulinum toxin formulation, for which the company is pursuing cGMP certification to enter advanced markets such as the United States.
The company plans to utilize its Osong Plants 2 and 3 as outposts for global expansion and is establishing a strategy for each overseas country and going through the certification process.
The liquid toxin formulation, MT10109L, which the company plans to take to advanced markets such as the U.S., is targeted for a U.S. Food and Drug Administration (FDA) biologics license application (BLA) within the year based on the results of the U.S. Phase 3 clinical trial.
[WIKI KOREA=Cho Pil Hyun, Staff Reporter]
chop23@wikileaks-kr.org
